GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneOne Life Science Inc (XKRX:011000) » Definitions » Cyclically Adjusted FCF per Share

GeneOne Life Science (XKRX:011000) Cyclically Adjusted FCF per Share : ₩0.00 (As of Mar. 2025)


View and export this data going back to 1987. Start your Free Trial

What is GeneOne Life Science Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

GeneOne Life Science's adjusted free cash flow per share for the three months ended in Mar. 2025 was ₩0.000. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ₩0.00 for the trailing ten years ended in Mar. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -8.30% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -15.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of GeneOne Life Science was 9.30% per year. The lowest was -23.00% per year. And the median was -9.30% per year.

As of today (2025-05-19), GeneOne Life Science's current stock price is ₩2660.00. GeneOne Life Science's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was ₩0.00. GeneOne Life Science's Cyclically Adjusted Price-to-FCF of today is .


GeneOne Life Science Cyclically Adjusted FCF per Share Historical Data

The historical data trend for GeneOne Life Science's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneOne Life Science Cyclically Adjusted FCF per Share Chart

GeneOne Life Science Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -254.92 -362.96 -439.07 -474.22 -460.66

GeneOne Life Science Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -475.33 -459.31 -493.29 -460.66 -

Competitive Comparison of GeneOne Life Science's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, GeneOne Life Science's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneOne Life Science's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneOne Life Science's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GeneOne Life Science's Cyclically Adjusted Price-to-FCF falls into.


;
;

GeneOne Life Science Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GeneOne Life Science's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0/122.5900*122.5900
=0.000

Current CPI (Mar. 2025) = 122.5900.

GeneOne Life Science Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.034 100.051 -0.042
201509 -21.149 100.111 -25.898
201512 27.547 100.220 33.696
201603 31.860 100.561 38.839
201606 -53.688 100.791 -65.300
201609 -300.780 101.461 -363.416
201612 -110.621 101.561 -133.526
201703 -13.541 102.851 -16.140
201706 -152.039 102.611 -181.641
201709 -45.434 103.491 -53.819
201712 55.278 102.991 65.797
201803 -14.133 104.101 -16.643
201806 -177.574 104.130 -209.053
201809 -10.734 105.651 -12.455
201812 -67.468 104.351 -79.261
201903 144.378 104.491 169.386
201906 -70.706 104.881 -82.645
201909 -47.105 105.200 -54.891
201912 -140.952 105.121 -164.375
202003 -89.323 105.354 -103.936
202006 -38.150 105.112 -44.494
202009 -129.529 106.198 -149.523
202012 -221.713 105.765 -256.982
202103 -187.299 107.357 -213.875
202106 -273.996 107.579 -312.229
202109 -334.792 108.759 -377.367
202112 -363.820 109.676 -406.657
202203 -319.462 111.848 -350.143
202206 -182.623 114.072 -196.259
202209 -165.755 114.715 -177.133
202212 -230.410 115.179 -245.235
202303 -144.072 116.507 -151.594
202306 -108.553 117.182 -113.563
202309 -8.952 118.964 -9.225
202312 -91.143 118.837 -94.021
202403 -82.177 120.123 -83.865
202406 -80.405 120.007 -82.135
202409 -52.607 120.861 -53.359
202412 -29.462 121.135 -29.816
202503 0.000 122.590 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


GeneOne Life Science  (XKRX:011000) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


GeneOne Life Science Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of GeneOne Life Science's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneOne Life Science Business Description

Traded in Other Exchanges
N/A
Address
343, Hakdong-ro, Gangnam-Gu, Seoul, KOR
GeneOne Life Science Inc is engaged in the research, development, and manufacturing of biopharmaceutical products including vaccines for treating pandemic influenza, seasonal influenza for old people, and chronic hepatitis B and C as well cancers and other infectious diseases.

GeneOne Life Science Headlines

No Headlines